Abstract:Objective To investigate the therapeutic effect of Vitamin A on the recovery of dry eye that was induced by benzalkonium chloride (BAC) topical medication in the mouse.Methods In this randomized controlled experimental study,50 BALB/c mice were treated with the topical administration of 0.25％ BAC to establish the dry eye condition.Based on the consistency of tear film break-up time (BUT),corneal fluorescein staining scores and inflammation index,the eyes were re-selected and 30 mice were randomly divided into three groups on day 21 after the BAC treatment,with 10 mice (20 eyes) in each group.Group C was set up as a blank control,while groups A and B were treated with 5000 IU/(g·ml) Vitamin A eye drops and microemulsion solvent drops,respectively.BUTs,corneal fluorescein staining scores,inflammation index and tear volumes were evaluated in each group on days 0,1,3,5 and 7 after the therapeutic treatment.Global specimens were collected on day 7.Sections were stained with hematoxylin and eosin (HE) or by periodic acid-Schiff (PAS) assay,and labeled with cytokeratin 10 (K10) antibody.The expression of K10 in the cornea and conjunctiva was quantified by Western Blot.The data were analyzed by one-way ANOVAs.Results On days 0,1,3 and 5,no clinical differences were observed among the groups.On day 7,the BUT values were (4.20±0.89)s,(3.32±1.01)s and (3.28±0.74)s in groups A,B and C,respectively.The BUT in group A was significantly longer than those in groups B and C (F=6.852,P=0.002).The corneal fluorescein staining scores were 3.74±1.31,5.47±1.81 and 5.83±1.54 in groups A,B and C,respectively.The scores in group A were significantly lower than those in groups B and C (F=8.853,P＜0.01).No significant differences were found in the corneal inflammatory index or tear volume among the groups.Corneal morphology showed a loosened corneal epithelium feature in groups B and C,but comeal integrity in group A.PAS assay revealed similar goblet cell numbers between group A and normal eyes,but fewer goblet cells in groups B and C.Cytokeratin 10 was almost negatively expressed in Vitamin A treated groups,while it remained positive in the entire corneal epithelial layer with other treatments.The level of K10 in the cornea was down-regulated in Vitamin A treated groups.Conclusion Vitamin A treatment presented marked therapeutic effects on BAC-induced mouse dry eye,with a more stable tear film,better recovery of epithelial integrity,an increased number of goblet cells,and the elimination of squamous metaplasia,when compared to the treatment of microemulsion solvent eye drops only or without treatment.This experiment show the great potential of Vitamin A in the clinical treatment of dry eye.

Cytisine eye drops for benzalkonium chloride-induced dry eye: safety and efficacy evaluation

Cyclosporine A (0.05%) Ophthalmic Gel in the Treatment of Dry Eye Disease: A Multicenter, Randomized, Double-Masked, Phase III, COSMO Trial

Therapeutic Effects of Topical Application of Lycium Barbarum Polysaccharide in a Murine Model of Dry Eye

Therapeutic Effects of Topical Doxycycline in A Benzalkonium Chloride-Induced Mouse Dry Eye Model

Ectoine, from a Natural Bacteria Protectant to a New Treatment of Dry Eye Disease

Therapeutic Effects of Epidermal Growth Factor on Benzalkonium Chloride-Induced Dry Eye in A Mouse Model

A mouse dry eye model induced by topical administration of benzalkonium chloride.

Efficacy, Safety, and Tolerability of a Novel Cyclosporine, a Formulation for Dry Eye Disease: A Multicenter Phase II Clinical Study

Cationorm shows good tolerability on human HCE-2 corneal epithelial cell cultures

Study on the preparation of chitosan artificial tear and its mitigation effect on rat dry eye

Chondroitin sulfate and L-Cysteine conjugate modified cationic nanostructured lipid carriers: Pre-corneal retention, permeability, and related studies for dry eye treatment

Protective Effect of Allyl Isothiocyanate in an Experimentally Induced Rat Model for Dry Eye Syndrome

In Vitro Cytotocity of Benzalkonium Chloride

M2 macrophage-derived extracellular vesicles ameliorate Benzalkonium Chloride-induced dry eye

DZ2002 alleviates corneal angiogenesis and inflammation in rodent models of dry eye disease via regulating STAT3-PI3K-Akt-NF-κB pathway

Amniotic membrane extract ameliorates benzalkonium chloride-induced dry eye in a murine model

Therapeutic Effects of Vitamin A on Mouse Dry Eye Induced by Benzalkonium Chloride Topical Medication

Recombinant Human Thymosin β4 (rhTβ4) Modulates the Anti-Inflammatory Responses to Alleviate Benzalkonium Chloride (BAC)-Induced Dry Eye Disease

Comparison of Treatment Effect and Tolerance of the Topical Application of Mizoribine and Cyclosporine A in a Mouse Dry Eye Model.

Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease: A Multicenter Randomized Trial

Therapeutic Potential of Crocin and Nobiletin in a Mouse Model of Dry Eye Disease: Modulation of the Inflammatory Response and Protection of the Ocular Surface